Prostate Cancer Phase 1/2a Study
This study is to assess the safety, tolerability and pharmacokinetics of OTL78, a PSMA-targeted fluorescent marker, for the intraoperative imaging of prostate cancer (Status: Enrollment Complete).
Learn MoreThe cancers we’re targeting
make up nearly
of all inpatient
oncology procedures
Our portfolio has the
potential to impact
procedures annually, across a
variety of surgical approaches
On Target Laboratories is the first to utilize small molecule technology to target unique characteristics of cancer cells, providing a clear differentiation between healthy and malignant tissue in the operating room. The benefit of small molecules is that they move through the body quickly. This quick action allows for flexible dosing schedules prior to surgery and minimal impact to workflow in the operating room.
Once our molecules reach their target they are endocytosed and remain inside the cancer cells throughout the length of the procedure.
Each small molecule is attached to a fluorescent dye that “lights up” malignant lesions via a near-infrared imaging system.
Because the imaging system, coupled with our bright dye, operates in the near-infrared spectrum, it optimizes visibility – even in lesions that are below the tissue surface.